Evaluating the inhibitory potential of sulindac against the bleomycin-induced pulmonary fibrosis in wistar rats

Environmental Toxicology and Pharmacology

Volumn 36, Issue 3, 2013, Pages 769-778

  Verma, Ramesh ^a   Brahmankar, Mahesh ^a   Kushwah, Lokendra ^a   Suresh, Balakrishnan ^b  

^a Jai Research Foundation   (India)

^b M S UNIVERSITY OF BARODA   (India)

Author keywords

Bleomycin; Hydroxyproline; Lung fibrosis; Sulindac; Tumour necrosis factor

Indexed keywords

BLEOMYCIN; CATALASE; COLLAGEN; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HYDROXYPROLINE; SULINDAC; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; EXPERIMENTAL RAT; HISTOPATHOLOGY; LEUKOCYTE DIFFERENTIAL COUNT; LIPID PEROXIDATION; LUNG FIBROSIS; LUNG LAVAGE; LUNG WEIGHT; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; WEIGHT GAIN; WEIGHT REDUCTION;

BLEOMYCIN; HYDROXYPROLINE; LUNG FIBROSIS; SULINDAC; TUMOUR NECROSIS FACTOR-Α;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; BODY WEIGHT; BRONCHOALVEOLAR LAVAGE FLUID; CATALASE; CELL COUNT; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HYDROXYPROLINE; LIPID PEROXIDATION; LUNG; MALE; ORGAN SIZE; PULMONARY FIBROSIS; RATS; RATS, WISTAR; SULINDAC; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84883017949     PISSN: 13826689     EISSN: 18727077     Source Type: Journal    
DOI: 10.1016/j.etap.2013.07.011     Document Type: Article

References (49)

1. Arafa H.M.M., Abdel-Wahab M.H., El-Shafeey M.F., Badary O.A., Hamada F.M.A. Antifibrotic effect of meloxicam in a murine lung fibrosis model. European Journal of Pharmacology 2007, 564:181-189.
2. Atzori L., Chua F., Dunsmore S.E., Willis D., Barbarisi M., McAnulty R.J., Laurent G.J. Attenuation of bleomycin induced pulmonary fibrosis in mice using the heme oxygenase inhibitor Zn-deuteroporphyrin IX-2,4-bisethylene glycol. Thorax 2004, 59:217-223.
3. Berman K., Verma U.N., Harburg G., Minna J.D., Cobb M.H., Gaynor R.B. Sulindac enhances tumor necrosis factor-α-mediated apoptosis of lung cancer cell lines by inhibition of nuclear factor-κB. Clinical Cancer Research 2002, 8:354-360.
4. Blum J., Fridovich I. Inactivation of glutathione peroxidase by superoxide radical. Archives of Biochemistry and Biophysics 1985, 240:500-508.
5. Coker R.K., Laurent G.J. Pulmonary fibrosis: cytokines in the balance. European Respiratory Journal 1998, 11:1218-1221.
6. Cooper J.A.D. Pulmonary fibrosis. American Journal of Respiratory Cell and Molecular Biology 2000, 22:520-523.
7. Daba M.H., Abdel-Aziz A.A., Moustafa A.M., Al-Majed A.A., Al-Shabanah O.A., El-Kashef H.A. Effect of l-carnitine and gingko biloba extract (EG b 761) in experimental bleomycin-induced lung fibrosis. Pharmacological Research 2002, 45:461-467.
8. Dairam A., Muller A.C., Daya S. Non-steroidal anti-inflammatory agents, tolmetin and sulindac attenuate quinolinic acid (QA)-induced oxidative stress in primary hippocampal neurons and reduce QA-induced spatial reference memory deficits in male Wistar rats. Life Sciences 2007, 80:1431-1438.
9. Edwards C.A., O'brien W.D.J.R. Modified assay for determination of hydroxyproline in a tissue hydrolyzate. Clinica Chimica Acta 1980, 104:161-167.
10. El-Khatib A.S. Possible modulatory role of nitric oxide in lung toxicity induced in rats by chronic administration of bleomycin. Chemotherapy 2002, 48:244-251.
11. Ellman G.L. Tissue sulfhydryl groups. Applied Biochemistry and Biotechnology 1959, 82:48670-48677.
12. El-Medany A., Hagar H.H., Moursi M., Muhammed R.A., El-Rakhawy F.I., El-Medany G. Attenuation of bleomycin induced lung fibrosis in rats by mesna. European Journal of Pharmacology 2005, 509:61-70.
13. Fernandes E., Toste S.A., Lima J.L.F.C., Reis S. The metabolism of sulindac enhances its scavenging activity against reactive oxygen and nitrogen species. Free Radical Biology and Medicine 2003, 35:1008-1017.
14. Filderman A.E., Genovese L.A., Lazo J.S. Alteration in pulmonary protective enzymes following systemic bleomycin treatment in mice. Biochemical Pharmacology 1988, 37:1111-1116.
15. Gad S.C., Weil C.S. Statistics for toxicology. Principles and Methods of Toxicology 1994, 221-274. Raven Press Ltd., New York. 3rd ed. A.W. Hayes (Ed.).
16. Gazdhar A., Fachinger P., Leer C.V., Pierog J., Gugger M., Friis R., Schmid R.A., Geiser T. Gene transfer of hepatocyte growth factor by electroporation reduces bleomycin-induced lung fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology 2007, 292:529-536.
17. Gong L., Li X., Wang H., Zhang L., Chen F., Cai Y., Qi X., Liu L., Liu Y., Xiong-fei Wu X., Huang C., Ren J. Effect of Feitai on bleomycin-induced pulmonary fibrosis in rats. Journal of Ethnopharmacology 2005, 96:537-544.
18. Green F.H.Y. Overview of pulmonary fibrosis. Chest 2002, 122:334-339.
19. Grunert R.R., Philips P.H. A modification of the nitroprusside method of analysis for glutathione. Applied Biochemistry and Biotechnology 1951, 30:217-225.
20. Jules-Elysee K., White D.A. Bleomycin-induced pulmonary toxicity. Clinics in Chest Medicine 1990, 11:1-20.
21. Kakkar P., Das B., Viswanathan P.N. A Modified spectrophotometric assay of superoxide dismutase. Indian Journal of Biochemistry and Biophysics 1984, 21:130-132.
22. Kalayarasan S., Sriram N., Sudhandiran G. Diallyl sulfide attenuates bleomycin-induced pulmonary fibrosis: critical role of iNOS, NF-κB, TNF-α and IL-1β. Life Sciences 2008, 82:1142-1153.
23. Keane M.P., Belperio J.A., Burdick M.D., Strieter R.M. IL-12 attenuates bleomycin induced pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology 2001, 281:92-97.
24. Liang X., Qiong Tian Q., Wei Z., Liu F., Chen J., Zhao Y., Ping Qu P., Huang X., Zhou X., Liu N., Tian F., Tie R., Liu L., Yu J. Effect of Feining on bleomycin-induced pulmonary injuries in rats. Journal of Ethnopharmacology 2011, 134:971-976.
25. Luck H. A spectrophotometric method for the estimation of catalase. Methods of Enzymatic Analysis 1963, 886-887. Academic Press, New York. H.U. Bergmeyer (Ed.).
26. Manoury B., Nenan S., Leclerc O., Guenon I., Boichot E., Planquois J., Bertrand C.P., Lagente V. The absence of reactive oxygen species production protects mice against bleomycin-induced pulmonary fibrosis. Respiratory Research 2005, 6:11.
27. Ohkawa H., Ohishi N., Yagi K. Assay of lipoperoxides in animal tissues by thiobarbituric acid reaction. Analytical Biochemistry 1979, 95:351-358.
28. Ortiz L.A., Champion H.C., Lasky J.A., Gambelli F., Gozal E., Hoyle G.W., Beasley M.B., Hyman A.L., Friedman M., Kadowitz J. Enalapril protects mice from pulmonary hypertension by inhibiting TNF-mediated activation of NF-kB and AP-1. American Journal of Physiology - Lung Cellular and Molecular Physiology 2002, 282:1209-1221.
29. Ozyurt H., Sogut S., Yildirim Z., Kart L., Iraz M., Armutcu F., Temel I., Ozen S., Uzun A., Akyol O. Inhibitory effect of caffeic acid phenyl ester on bleomycin induced lung fibrosis in rats. Clinica Chimica Acta 2004, 339:65-75.
30. Paglia D.E., Valentine W.N. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. Journal of Laboratory and Clinical Medicine 1967, 70:158-169.
31. Pardo A., Ruiz V., Arreola J.L., Ramirez R., Cisneros-Lira J., Gaxiola M., Barrios R., Kala S.V., Lieberman M.W., Selman M. Bleomycin-induced pulmonary fibrosis is attenuated in γ glutamyl transpeptidase-deficient mice. American Journal of Respiratory and Critical Care Medicine 2003, 167:925-932.
32. Razzaque M.S., Taguchi T. Pulmonary fibrosis: cellular and molecular events. Pathology International 2003, 53:133-145.
33. Serrano-Molar A., Closa D., Prats N., Blesa S., Martinez-Losa M., Cortijo J., Estrela J.M., Morcillo E.J., Bulbena O. In-vivo antioxidant treatment protects against bleomycin induced lung damage in rats. British Journal of Pharmacology 2003, 138:1037-1048.
34. Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001, 120:617-624.
35. Sogut S., Ozyurt H., Armutcu F., Kart L., Iraz M., Akyol O., Ozen S., Kaplan S., Temel I., Yildirim Z. Erdosteine prevents belomycin-induced pulmonary fibrosis in rats. European Journal of Pharmacology 2004, 494:213-220.
36. Soumyakrishnan S., Sudhandiran G. Daidzein attenuates inflammation and exhibits antifibrotic effect against bleomycin-induced pulmonary fibrosis in Wistar rats. Biomedicine and Preventive Nutrition 2011, 1:236-244.
37. Sriram N., Kalayarasan S., Sudhandiran G. Epigallocatechin-3-gallate augments antioxidant activities and inhibits inflammation during bleomycin-induced experimental pulmonary fibrosis through Nrf2-Keap1 signaling. Pulmonary Pharmacology and Therapeutics 2009, 22:221-236.
38. Szapiel S.V., Elson N.A., Fulmer J.D., Hunninghake G.W., Crystal R.G. Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse. American Review of Respiratory Diseases 1979, 120:893-899.
39. Teixeira K.C., Soares F.S., Rocha L.G., Silveira P.C., Silva L.A., Valenca S.S., Dal Pizzol F., Streck E.L., Pinhoa R.A. Attenuation of bleomycin-induced lung injury and oxidative stress by N-acetylcysteine plus deferoxamine. Pulmonary Pharmacology and Therapeutics 2008, 21:309-316.
40. Tzurel A., Segel M.J., Or R., Goldstein R.H., Breuer R. Halofuginone does not reduce fibrosis in bleomycin-induced lung injury. Life Sciences 2002, 71:1599-1606.
41. Vaish V., Sanyal S.N. Role of sulindac and celecoxib in the regulation of angiogenesis during the early neoplasm of colon: Exploring PI3-K/PTEN/Akt pathway to the canonical Wnt/b-catenin signaling. Biomedicine and Pharmacotherapy 2012, 66:354-367.
42. Vane J.R., Bakhle Y.S., Botting R.M. Cyclooxygenases 1 and 2. Annual Review of Pharmacology and Toxicology 1998, 38:97-120.
43. Wang H.D., Yamaya M., Okinaga S., Jia Y.X., Kamanaka M., Takahashi H., Guo L.Y., Ohrui T., Sasaki H. Bilirubin ameliorates bleomycin-induced pulmonary fibrosis in rats. American Journal of Respiratory and Critical Care Medicine 2002, 165:406-411.
44. Wang Q.J., Giri S.N., Hyde D.M., Li C. Amelioration of bleomycin-induced pulmonary fibrosis in hamsters by combined treatment with taurine and niacin. Biochemical Pharmacology 1991, 42:1115-1122.
45. Xin Wei X., Han J., Chen Z., Qi B., Wang G., Ma Y., Zheng H., Luo Y., Wei Y., Chen L. A phosphoinositide 3-kinase-γ inhibitor, AS605240 prevents bleomycin-induced pulmonary fibrosis in rats. Biochemical and Biophysical Research Communications 2010, 397:311-317.
46. Yara S., Kawakami K., Kudeken N., Tohyama M., Teruya K., Chinen T., Awaya A., Saito A. FTS reduces bleomycin-induced cytokine and chemokine production and inhibits pulmonary fibrosis in mice. Clinical and Experimental Immunology 2001, 124:77-85.
47. Yildirim Z., Turkoz Y., Kotuk M., Armutcu F., Gurel A., Iraz M., Ozen S., Aydogdu I., Akyol O. Effects of aminoguanidine and antioxidant erdosteine on bleomycin-induced lung fibrosis in rats. Nitric Oxide 2004, 11:156-165.
48. Zhao L., Wang X., Chang O., Xu J., Huang Y., Guo Q., Zhang S., Wang W., Chen X., Wang J. Neferine, a bisbenzylisoquinline alkaloid attenuates bleomycin induced pulmonary fibrosis. European Journal of Pharmacology 2010, 627:304-312.
49. Zhou X., Zhang G., Li C., Hou J. Inhibitory effects of Hu-qi-yin on the bleomycin-induced pulmonary fibrosis in rats. Journal of Ethnopharmacology 2007, 111:255-264.